Literature DB >> 30918866

Incidence of hypoglycaemia in patients with type-2 diabetes taking multiple glucose lowering therapies during Ramadan: the PROFAST Ramadan Study.

Tarik Elhadd1, Zeinab Dabbous1, Mohammed Bashir1, Abdulnasir Elzouki1, Wissam Ghadban1, Khaled Baagar1, Silas Benjamin1, Mohamed Hassanien2, Abazar A M Saeed1, Khaled Dukhan1, Rayaz A Malik3, Abdul-Badie Abou-Samra1.   

Abstract

OBJECTIVE: To assess the incidence of hypoglycemia in people with type-2 diabetes mellitus (T2DM) on three or more anti-diabetic medications during Ramadan. STUDY DESIGN
METHODS: We have studied people with T2DM on three or more glucose-lowering drugs during Ramadan of H1438 (May-June 2017). The dose of each drug was adjusted according to a pre-specified protocol. The incidence of symptomatic or blood glucose confirmed hypoglycemia was recorded during the study.
RESULTS: We enrolled 228 people with T2DM; 181 completed the study, and data on hypoglycaemia was available in 172 subjects. There were 115 males and 66 females, (mean age ± SD) 53.6 ± 9.7 years, diabetes duration 10 ± 6 yrs. The incidence of hypoglycaemia was 16.3% (28/172). Univariable logistic regression analysis showed that the risk of hypoglycaemia was increased in Arab subjects compared to Qatari; in those with longer duration of diabetes; and in those on four or more anti-diabetic medications compared to those on three anti-diabetic medications.
CONCLUSION: Despite the tailored advice, there is a high incidence of hypoglycemia in people with T2DM taking multiple glucose lowering therapies whilst fasting during Ramadan. Guidelines should address the increased complexity in anti-diabetic medications in patients who fast during Ramadan. Healthcare providers should individualize the modifications in anti-diabetic medications during Ramadan.

Entities:  

Keywords:  Hypoglycaemia; IDF; Ramadan; Type 2 diabetes

Year:  2018        PMID: 30918866      PMCID: PMC6405393          DOI: 10.1007/s40200-018-0374-2

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  22 in total

1.  A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.

Authors:  Mustafa Cesur; Demet Corapcioglu; Alptekin Gursoy; Sait Gonen; Mine Ozduman; Rifat Emral; Ali Riza Uysal; Vedia Tonyukuk; Arif Ender Yilmaz; Fahri Bayram; Nuri Kamel
Journal:  Diabetes Res Clin Pract       Date:  2006-07-03       Impact factor: 5.602

Review 2.  Diabetes and Ramadan: Practical guidelines.

Authors:  Mohamed Hassanein; Monira Al-Arouj; Osama Hamdy; Wan Mohamad Wan Bebakar; Abdul Jabbar; Abdulrazzaq Al-Madani; Wasim Hanif; Nader Lessan; Abdul Basit; Khaled Tayeb; Mak Omar; Khalifa Abdallah; Abdulaziz Al Twaim; Mehmet Akif Buyukbese; Adel A El-Sayed; Abdullah Ben-Nakhi
Journal:  Diabetes Res Clin Pract       Date:  2017-03-12       Impact factor: 5.602

3.  Drug treatment during Ramadan. Don't be complacent about diabetes.

Authors:  A E Gold; K M MacLeod; B M Frier
Journal:  BMJ       Date:  1993-09-25

4.  Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.

Authors:  S R Aravind; Khaled Al Tayeb; Shaiful Bahari Ismail; Naim Shehadeh; Ghaida Kaddaha; Rose Liu; Robert Balshaw; Nadia Lesnikova; Olaf Heisel; Cynthia J Girman; Bret J Musser; Michael J Davies; Harvey L Katzeff; Samuel S Engel; Larry Radican
Journal:  Curr Med Res Opin       Date:  2011-04-20       Impact factor: 2.580

5.  Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.

Authors:  Okan Bakiner; Melek E Ertorer; Emre Bozkirli; Neslihan B Tutuncu; Nilgun G Demirag
Journal:  Acta Diabetol       Date:  2008-09-30       Impact factor: 4.280

6.  A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study.

Authors:  Ibrahim Salti; Eric Bénard; Bruno Detournay; Monique Bianchi-Biscay; Corinne Le Brigand; Céline Voinet; Abdul Jabbar
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

7.  The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.

Authors:  Ramazan Sari; Mustafa Kemal Balci; Sadika Halide Akbas; Berkant Avci
Journal:  Endocr Res       Date:  2004-05       Impact factor: 1.720

8.  Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes.

Authors:  Alaaeldin Bashier; Azza Abdulaziz Khalifa; Elamin Ibrahim Abdelgadir; Maryam Ahmad Al Saeed; Amina Adil Al Qaysi; Murad Burhan Ali Bayati; Budoor Alemadi; Fawzi Bachet; Fatheya Alawadi; Mohammed Hassanein
Journal:  Oman Med J       Date:  2018-03

Review 9.  Hypoglycaemia in Type 2 diabetes.

Authors:  S A Amiel; T Dixon; R Mann; K Jameson
Journal:  Diabet Med       Date:  2008-01-21       Impact factor: 4.359

10.  The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.

Authors:  M Al-Arouj; A A K Hassoun; R Medlej; M F Pathan; I Shaltout; M S Chawla; S Hristoskova; S Ditommaso; M Y Kadwa
Journal:  Int J Clin Pract       Date:  2013-09-03       Impact factor: 2.503

View more
  1 in total

1.  Sex as a Biological Factor in the Changes in Disease Patients During Ramadan Intermittent Fasting: A Systematic Review.

Authors:  Rachida Roky; Nadia Aadil; Al Mehdi Krami; Brahim Benaji; Ikram Errabih; Dana N Abdelrahim; MoezAlIslam Ezzat Faris
Journal:  Front Nutr       Date:  2022-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.